Author + information
- S1936879815022062-60ebabd830a36f69c4fb5bbb1a71e8cfMohammed Ahmed1,
- S1936879815022062-07d72b2429f82ff8fc2f8fc51376bbe5Hafeez Ul-Hassan1,
- S1936879815022062-f8e3bfec20963eb89c6868287983ee0cLubna Muneer2 and
- S1936879815022062-34c2338f86b0b9b830017f55310e4a5cSaurav Chatterjee1
Current metallic stents safeguard vessel patency, but long term complications include in-stent thrombosis. Theoretically, bioresorbable scaffolding should reduce the risk of in-stent thrombosis while maintaining early vessel patency.
A meta-analysis of the available randomized control trials.
Medline, Google Scholar, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) database were searched for randomized controlled trials comparing Absorb BVS with durable polymer EES.
Efficacy (Target Lesion Revascularization (TLR)), and safety (definite or probable stent thrombosis, one year mortality).
Five randomized controlled trials included 2259 patients of coronary artery disease treated with a BVS versus 1383 patients treated with EES. There was no significant difference in the incidence of TLR (Relative Risk (RR): 1.08, 95% Confidence Interval (CI): 0.74 - 1.58), definite/probable stent thrombosis (RR 2.00 95% CI: 0.93 - 4.30), 1 year mortality (RR: 1.79, 95% CI: 0.13 - 25.40).
BVS is non-inferior to EES with respect to TLR, stent thrombosis and death.